AbbVie (ABBV) Income towards Parent Company (2012 - 2026)
AbbVie's (ABBV) quarterly Income towards Parent Company came in at $3.6 billion in Q2 2026, up 284.27% year-over-year from $941.0 million in Q2 2025, and up 418.79% quarter-over-quarter from $697.0 million in Q1 2026.
Analysis
AbbVie (ABBV) Income towards Parent Company (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Income towards Parent Company for 15 consecutive years, with $3.6 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Income towards Parent Company rose 284.27% year-over-year to $3.6 billion in Q2 2026; TTM through Jun 2026 was $6.3 billion, a 67.49% increase from a year earlier, with the FY2025 full-year figure at $4.2 billion, down 1.24% from the prior year.
- Income towards Parent Company was $3.6 billion for Q2 2026 at AbbVie, up from $697.0 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $4.5 billion in Q1 2022 and troughed at -$97.0 million in Q1 2023.
- A 5-year average of $1.6 billion and a median of $1.4 billion in 2024 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company plunged 102.79% in 2024 and jumped 7991.3% in 2025, its largest moves.
- Over 5 years, Income towards Parent Company stood at $2.5 billion in 2022, then slumped by 66.67% to $824.0 million in 2023, then sank by 102.79% to -$23.0 million in 2024, then jumped by 7991.3% to $1.8 billion in 2025, then soared by 99.23% to $3.6 billion in 2026.
- The last three Income towards Parent Company figures came in at $3.6 billion (Q2 2026), $697.0 million (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.62 Bn |
| Mar 31, 2026 | 697.00 Mn |
| Dec 31, 2025 | 1.82 Bn |
| Sep 30, 2025 | 188.00 Mn |
| Jun 30, 2025 | 941.00 Mn |
| Mar 31, 2025 | 1.29 Bn |
| Dec 31, 2024 | -23.00 Mn |
| Sep 30, 2024 | 1.56 Bn |
| Jun 30, 2024 | 1.37 Bn |
| Mar 31, 2024 | 1.37 Bn |
| Dec 31, 2023 | 824.00 Mn |
| Sep 30, 2023 | 1.78 Bn |
| Jun 30, 2023 | 2.03 Bn |
| Mar 31, 2023 | -97.00 Mn |
| Dec 31, 2022 | 2.47 Bn |
| Sep 30, 2022 | 3.95 Bn |
| Jun 30, 2022 | 928.00 Mn |
| Mar 31, 2022 | 4.49 Bn |
| Dec 31, 2021 | 4.05 Bn |
| Sep 30, 2021 | 3.18 Bn |